Overview

Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris

Status:
Completed
Trial end date:
2019-09-05
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.
Phase:
Phase 2
Details
Lead Sponsor:
Botanix Pharmaceuticals